Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
10 2021
Historique:
received: 02 06 2021
revised: 28 06 2021
accepted: 29 06 2021
pubmed: 7 8 2021
medline: 24 9 2021
entrez: 6 8 2021
Statut: ppublish

Résumé

In children, SARS-CoV-2 infection is usually asymptomatic or causes a mild illness of short duration. Persistent illness has been reported; however, its prevalence and characteristics are unclear. We aimed to determine illness duration and characteristics in symptomatic UK school-aged children tested for SARS-CoV-2 using data from the COVID Symptom Study, one of the largest UK citizen participatory epidemiological studies to date. In this prospective cohort study, data from UK school-aged children (age 5-17 years) were reported by an adult proxy. Participants were voluntary, and used a mobile application (app) launched jointly by Zoe Limited and King's College London. Illness duration and symptom prevalence, duration, and burden were analysed for children testing positive for SARS-CoV-2 for whom illness duration could be determined, and were assessed overall and for younger (age 5-11 years) and older (age 12-17 years) groups. Children with longer than 1 week between symptomatic reports on the app were excluded from analysis. Data from symptomatic children testing negative for SARS-CoV-2, matched 1:1 for age, gender, and week of testing, were also assessed. 258 790 children aged 5-17 years were reported by an adult proxy between March 24, 2020, and Feb 22, 2021, of whom 75 529 had valid test results for SARS-CoV-2. 1734 children (588 younger and 1146 older children) had a positive SARS-CoV-2 test result and calculable illness duration within the study timeframe (illness onset between Sept 1, 2020, and Jan 24, 2021). The most common symptoms were headache (1079 [62·2%] of 1734 children), and fatigue (954 [55·0%] of 1734 children). Median illness duration was 6 days (IQR 3-11) versus 3 days (2-7) in children testing negative, and was positively associated with age (Spearman's rank-order r Although COVID-19 in children is usually of short duration with low symptom burden, some children with COVID-19 experience prolonged illness duration. Reassuringly, symptom burden in these children did not increase with time, and most recovered by day 56. Some children who tested negative for SARS-CoV-2 also had persistent and burdensome illness. A holistic approach for all children with persistent illness during the pandemic is appropriate. Zoe Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging and Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation, and Alzheimer's Society.

Sections du résumé

BACKGROUND
In children, SARS-CoV-2 infection is usually asymptomatic or causes a mild illness of short duration. Persistent illness has been reported; however, its prevalence and characteristics are unclear. We aimed to determine illness duration and characteristics in symptomatic UK school-aged children tested for SARS-CoV-2 using data from the COVID Symptom Study, one of the largest UK citizen participatory epidemiological studies to date.
METHODS
In this prospective cohort study, data from UK school-aged children (age 5-17 years) were reported by an adult proxy. Participants were voluntary, and used a mobile application (app) launched jointly by Zoe Limited and King's College London. Illness duration and symptom prevalence, duration, and burden were analysed for children testing positive for SARS-CoV-2 for whom illness duration could be determined, and were assessed overall and for younger (age 5-11 years) and older (age 12-17 years) groups. Children with longer than 1 week between symptomatic reports on the app were excluded from analysis. Data from symptomatic children testing negative for SARS-CoV-2, matched 1:1 for age, gender, and week of testing, were also assessed.
FINDINGS
258 790 children aged 5-17 years were reported by an adult proxy between March 24, 2020, and Feb 22, 2021, of whom 75 529 had valid test results for SARS-CoV-2. 1734 children (588 younger and 1146 older children) had a positive SARS-CoV-2 test result and calculable illness duration within the study timeframe (illness onset between Sept 1, 2020, and Jan 24, 2021). The most common symptoms were headache (1079 [62·2%] of 1734 children), and fatigue (954 [55·0%] of 1734 children). Median illness duration was 6 days (IQR 3-11) versus 3 days (2-7) in children testing negative, and was positively associated with age (Spearman's rank-order r
INTERPRETATION
Although COVID-19 in children is usually of short duration with low symptom burden, some children with COVID-19 experience prolonged illness duration. Reassuringly, symptom burden in these children did not increase with time, and most recovered by day 56. Some children who tested negative for SARS-CoV-2 also had persistent and burdensome illness. A holistic approach for all children with persistent illness during the pandemic is appropriate.
FUNDING
Zoe Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging and Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation, and Alzheimer's Society.

Identifiants

pubmed: 34358472
pii: S2352-4642(21)00198-X
doi: 10.1016/S2352-4642(21)00198-X
pmc: PMC8443448
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

708-718

Subventions

Organisme : Medical Research Council
ID : MC_PC_20058
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests CH, SS, KR, and JCP are employees of Zoe Limited. TDS reports being a consultant for Zoe Limited, during the conduct of the study. All other authors declare no competing interests.

Références

Lancet Child Adolesc Health. 2021 May;5(5):e12-e13
pubmed: 33713603
J Child Psychol Psychiatry. 2007 Aug;48(8):785-92
pubmed: 17683450
Int J Pediatr Otorhinolaryngol. 2021 Mar;142:110626
pubmed: 33477014
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074-1080
pubmed: 32790663
Dev Med Child Neurol. 2010 Dec;52(12):1088-97
pubmed: 20875042
N Engl J Med. 2021 Feb 18;384(7):669-671
pubmed: 33406327
Lancet Child Adolesc Health. 2021 Jun;5(6):e22-e23
pubmed: 33891880
PLoS One. 2020 Nov 9;15(11):e0240784
pubmed: 33166287
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Infect Dis. 2013 Jan 1;207(1):80-8
pubmed: 23100562
Acta Paediatr. 2021 Mar;110(3):914-921
pubmed: 33205450
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Pediatrics. 2021 Sep;148(3):
pubmed: 34049958
Science. 2020 Jun 19;368(6497):1362-1367
pubmed: 32371477
Lancet Public Health. 2021 Jan;6(1):e21-e29
pubmed: 33278917
Arch Dis Child. 2017 Jun;102(6):522-528
pubmed: 28104625
Front Pediatr. 2020 Nov 02;8:591132
pubmed: 33224909
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Cochrane Database Syst Rev. 2020 Jul 7;7:CD013665
pubmed: 32633856
Br J Psychiatry. 2004 Jun;184:477-81
pubmed: 15172940
BMC Infect Dis. 2020 Aug 31;20(1):640
pubmed: 32867706
BMJ. 1994 Sep 24;309(6957):765-9
pubmed: 7950559
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
BMJ Open. 2011 Dec 12;1(2):e000252
pubmed: 22155938
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937

Auteurs

Erika Molteni (E)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Carole H Sudre (CH)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK; MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences and Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK.

Liane S Canas (LS)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Sunil S Bhopal (SS)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Robert C Hughes (RC)

Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Michela Antonelli (M)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Benjamin Murray (B)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Kerstin Kläser (K)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Eric Kerfoot (E)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Liyuan Chen (L)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Jie Deng (J)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Christina Hu (C)

Zoe Limited, London, UK.

Somesh Selvachandran (S)

Zoe Limited, London, UK.

Kenneth Read (K)

Zoe Limited, London, UK.

Joan Capdevila Pujol (J)

Zoe Limited, London, UK.

Alexander Hammers (A)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK; King's College London and Guy's and St Thomas' PET Centre, London, UK.

Tim D Spector (TD)

Department of Twin Research and Genetic Epidemiology, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Sebastien Ourselin (S)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Claire J Steves (CJ)

Department of Twin Research and Genetic Epidemiology, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK; Department of Ageing and Health, Guys and St Thomas' NHS Foundation Trust, London, UK.

Marc Modat (M)

School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.

Michael Absoud (M)

Department of Women and Children's Health, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK; Children's Neurosciences, Evelina London Children' Hospital, St Thomas' Hospital, King's Health Partners, Academic Health Science Centre, London, UK.

Emma L Duncan (EL)

Department of Twin Research and Genetic Epidemiology, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK; Department of Endocrinology, Guys and St Thomas' NHS Foundation Trust, London, UK. Electronic address: emma.duncan@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH